Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved...
28 KB (2,001 words) - 01:03, 31 August 2024
Cancer immunotherapy (section Ofatumumab)
CD20 protein, ofatumumab binds to a separate, small loop. This may explain their different characteristics. Compared to rituximab, ofatumumab induces complement-dependent...
92 KB (12,517 words) - 05:38, 1 October 2024
this disease, other anti-CD20 drugs such as ocrelizumab, veltuzumab, and ofatumumab have been explored as potential treatments. Key companies in Pemphigus...
17 KB (1,995 words) - 07:25, 30 October 2024
22-0.25 Zeposia Ozanimod [better source needed] Oral 0.18-0.24 Kesimpta Ofatumumab Subcutaneous 70% 0.09-0.14 Mavenclad Cladribine Oral 70% 0.1-0.14 Lemtrada...
170 KB (18,177 words) - 09:23, 7 November 2024
GlaxoSmithKline decided to exit oncology, which impacted co-development of ofatumumab, an oncology-directed product. In tandem with the sale of the plant, the...
26 KB (1,906 words) - 04:10, 19 June 2024
developed: ocrelizumab, humanized (90%-95% human) B cell-depleting agent. ofatumumab (HuMax-CD20) a fully human B cell-depleting agent. Third-generation anti-CD20s...
62 KB (5,670 words) - 03:38, 8 November 2024
CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active...
26 KB (2,953 words) - 04:22, 15 October 2024
company acquired the remaining rights to the CD20 monoclonal antibody Ofatumumab from GlaxoSmithKline for up to $1 billion. In October the company acquired...
144 KB (12,146 words) - 09:25, 31 October 2024
ibrutinib down-modulates the expression of CD20 (target of rituximab/ofatumumab) by targeting the CXCR4/SDF1 axis. Together, these data are consistent...
29 KB (2,605 words) - 21:22, 16 August 2024
Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal...
48 KB (4,964 words) - 04:26, 20 October 2024
in trade names. Examples include: HuMax-CD4 (zanolimumab) HuMax-CD20 (ofatumumab) HuMax-EGFr (zalutumumab) This set index article includes a list of related...
381 bytes (69 words) - 16:14, 6 May 2016
Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid:...
12 KB (821 words) - 02:57, 12 October 2024
July 2020. Retrieved 23 January 2020. "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients...
137 KB (4,083 words) - 21:25, 19 October 2024
3-kinase), as well as monoclonal antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab). Notably, some of the effects...
73 KB (7,597 words) - 22:02, 28 August 2024
Ocusert Pilo Ocusulf odanacatib (USAN) odronextamab (INN) odulimomab (INN) ofatumumab (INN) Ogivri oglufanide disodium (USAN) Ogsiveo Ohtuvayre Ojemda Ojjaara...
7 KB (376 words) - 05:53, 10 November 2024
Ocrelizumab L04AG09 Emapalumab L04AG10 Inebilizumab L04AG11 Anifrolumab L04AG12 Ofatumumab L04AG13 Teprotumumab L04AG14 Ublituximab L04AG15 Divozilimab L04AG16 Rozanolixizumab...
3 KB (367 words) - 15:37, 25 January 2024
monoclonal antibody, has been approved for some indications. Ocrelizumab, ofatumumab, and "third-generation" anti-CD20 monoclonals are in development.[citation...
31 KB (2,727 words) - 21:26, 26 January 2024
those diseases, as antibodies against CD20 exist: e.g. Rituximab and Ofatumumab, with several more in development. Similarly, anti-CD20 monoclonal antibody...
96 KB (467 words) - 19:33, 6 August 2024
Cedelizumab Emapalumab Fontolizumab Inebilizumab Maslimomab Morolimumab Ofatumumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox...
7 KB (299 words) - 13:45, 27 April 2024
Sitravatinib L01EX27 Capivasertib QL01EX90 Toceranib L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab...
12 KB (877 words) - 15:36, 25 January 2024
abnormal temperature increases, headache, abdominal pain, and vomiting. Ofatumumab IV Anti-CD20 antibody. Chronic lymphocytic leukaemia Neutropenia, pneumonia...
52 KB (708 words) - 12:37, 26 August 2024
completed pivotal phase III trial DUO comparing duvelisib monotherapy with ofatumumab led to its approval for CLL/SLL An extension trial to DUO was completed...
45 KB (5,359 words) - 22:07, 19 July 2024
in the clinic including Aimovig (erenumab) for migraine and Kesimpta (ofatumumab) for multiple sclerosis.[citation needed] Dolmetsch was also involved...
16 KB (1,617 words) - 22:42, 5 November 2024
Multiple myeloma Advanced melanoma Phase III A comparison of dinaciclib and ofatumumab for treatment of CLL Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar...
10 KB (872 words) - 12:24, 8 July 2024
Indication Ivacaftor Vertex Pharmaceuticals cystic fibrosis with CFTR mutation Ofatumumab Novartis Pharmaceuticals chronic lymphocytic leukemia Ceritinib Novartis...
34 KB (180 words) - 17:05, 14 October 2024
killing mechanism of some monoclonal antibodies like rituximab (Rituxan), ofatumumab (Azzera), and others. The contribution of antibody-dependent cell-mediated...
75 KB (9,227 words) - 23:32, 16 October 2024
Genentech 3/28/2017 intravenous humanized CD20 Multiple sclerosis 761053 Link ofatumumab Arzerra Glaxo Grp 10/26/2009 intravenous fully human CD20 Chronic lymphocytic...
59 KB (4,170 words) - 07:03, 20 October 2024
PCDLBCL, NOS and ultimately may prove useful in PCDLBCL, LT. These include: ofatumumab, a monoclonal antibody that is stronger than rituximab in binding to CD20;...
22 KB (2,669 words) - 05:05, 4 January 2024
beta-1b; monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatiramer acetate, mitoxantrone...
131 KB (14,021 words) - 13:06, 1 November 2024
Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid:...
12 KB (758 words) - 23:46, 14 March 2024